Evotec (EVO)
(Delayed Data from NSDQ)
$4.25 USD
+0.39 (9.96%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $4.26 +0.01 (0.24%) 6:42 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.25 USD
+0.39 (9.96%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $4.26 +0.01 (0.24%) 6:42 PM ET
4-Sell of 5 4
D Value D Growth A Momentum D VGM
Zacks News
Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY
by Zacks Equity Research
A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.
Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J
by Zacks Equity Research
Evotec (EVO) signs a collaboration agreement with Janssen, a wholly owned subsidiary of J&J, for discovering novel drugs in the field of protein homeostasis. Shares down.